# Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

> **NCT00983853** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 62 (actual)

## Conditions studied

- Hepatitis C
- HIV Infections

## Interventions

- **DRUG:** telaprevir or matching placebo
- **DRUG:** telaprevir or matching placebo
- **BIOLOGICAL:** peginterferon alfa-2a
- **DRUG:** ribavirin (fixed dose)
- **DRUG:** ribavirin (weight-based dose)

## Key facts

- **NCT ID:** NCT00983853
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2013-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00983853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00983853, "Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00983853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*